Gursukhman Deep Sidhu, MD
Cardiovascular Disease · Davenport, IANPI 1871930719
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (47.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Abbott at 43.2% of the total. Reporting peaked in 2023 at $24,330 and has fallen 71.7% since, to $6,891 in 2025. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $202.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$26K
- Medtronic$16K
- Boston Scientific$10K
- Medical Device Business Services, Inc.$3K
- Biotronik Inc.$2K
- Biosense Webster, Inc.$866
- plus $3K from 21 others
What the payments were for
- Grants$28,50047%
- Travel & lodging$17,42029%
- Food & beverage$11,98720%
- Education$2,2854%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 77 | $26,021 |
| Medtronic | 77 | $16,068 |
| Boston Scientific | 30 | $9,610 |
| Medical Device Business Services, Inc. | 18 | $2,840 |
| Biotronik Inc. | 16 | $1,603 |
| Biosense Webster, Inc. | 12 | $866 |
| Philips North America LLC | 4 | $691 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $392 |
| Johnson & Johnson | 12 | $309 |
| Novartis | 12 | $293 |
| Astellas Pharma US Inc | 3 | $256 |
| Actelion Pharmaceuticals US, Inc. | 2 | $162 |
| Boehringer Ingelheim | 3 | $158 |
| Lantheus Medical Imaging, Inc. | 1 | $129 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| Abiomed | 2 | $112 |
| Sanofi-aventis U.S. LLC | 1 | $112 |
| Volta Medical Inc | 1 | $105 |
| AstraZeneca | 4 | $64 |
| Terumo Medical Corporation | 2 | $55 |
| Pfizer | 3 | $52 |
| Cardiva Medical, Inc. | 2 | $46 |
| BD | 1 | $44 |
| Edwards Lifesciences | 1 | $29 |
| Amgen | 1 | $21 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Elutia, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$3,895
- ENSITE$3,150
- Carto 3$2,775
- Micra$1,525
- AMPLATZER AMULET$889
- Rhythmia Mapping System$828
- VersaCross Access Solution$482
- US Und$358
- AMVIA EDGE$299
- Selectra$299
- Solia$299
- PAMIRA$299
- SelectSecure$295
- EnSite Precision Cardiac Mapping System$246
- (9520) IGT Devices Undivided$219
- HeartMate 3 Left Ventricular Dev$214
- QDOT MICRO Catheter$146
- COREVALVE EVOLUT R$145
- CLARIA MRI QUAD CRT-D SURESCAN$130
- Definity$129
How this compares
$60,192 in reported general payments places this provider in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $12,927 |
| Flecainide Acetate | 16 | $455 |
| Metoprolol Succinate | 21 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52 | $12,92713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Davenport
- Jon RobkenDavenport$2K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Suzanne FeigofskyWest Des Moines$59K
- Tyler RasmussenCedar Rapids$37K
- Jennifer RobinsonIowa City$37K
- Matthew McMahonCedar Rapids$35K
- Craig StarkDes Moines$28K
- Tauseef KhanDubuque$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.